| 000 | 02022nam a2200277Ia 4500 | ||
|---|---|---|---|
| 000 | 03692naaa 00757uu | ||
| 001 | https://directory.doabooks.org/handle/20.500.12854/68320 | ||
| 005 | 20211222133724.0 | ||
| 008 | 211013s9999 xx 000 0 und d | ||
| 020 | _a9783039438716 | ||
| 024 | _a10.3390/books978-3-03943-872-3 | ||
| 042 | _adc | ||
| 245 | 0 | _aAdvance in Gluten-Free Diet | |
| 260 |
_aBasel, Switzerland _bMDPI - Multidisciplinary Digital Publishing Institute _c2021 |
||
| 300 | _a1 electronic resource (110 p.) | ||
| 506 | _aOpen Access | ||
| 520 | _aThe only effective and safe treatment of celiac disease (CD) is a lifelong, strict exclusion of gluten, the so-called gluten-free diet (GFD). As a consequence, strict adherence to the GFD is highly successful and useful to achieve optimal control of symptoms in celiac patients, although, sometimes, nutritional problems can persist despite a strict exclusion of gluten. However, following a strict GFD is not easy and an updated quality assessment of available products is needed for further improvement in gluten-free product development. Similar to CD, GFD is the common dietary approach in non-celiac gluten/wheat sensitivity (NCGWS). NCGWS is another common gluten-related disorder without the diagnostic features of CD. Increasing interest in the association and interaction between irritable bowel syndrome (IBS), functional dyspepsia, and gluten-related disorders can expand our knowledge and understanding of the management of these disorders. In this respect, GFD is considered a therapeutic option in IBS and functional digestive disorders. New insights into the GFD are an exciting scientific challenge for researchers. | ||
| 540 | _aCreative Commons | ||
| 653 | _airritable bowel syndrome | ||
| 700 | 1 | _aPaolo, Usai-Satta | |
| 700 | 1 | _aPaolo, Usai-Satta | |
| 856 | _uhttps://directory.doabooks.org/handle/20.500.12854/68320 | ||
| 856 | _uhttps://mdpi.com/books/pdfview/book/3330 | ||
| 856 | _uwww.oapen.org | ||
| 942 | _cE-BOOK | ||
| 999 |
_c43901 _d43901 |
||